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Abstract 
Malaria is an ubiquitous disease that can affect more than 40% of the worldÕs population who 
live with some risk of contracting this disease. The World Health Organization (WHO) has 
recently highlighted the high spread of this disease in Sub-Saharan Africa. Despite the 
considerable fall in mortality rate over the past decade, the development of resistance against 
main treatment strategies still exists. This problem has provoked scientific efforts to develop 
various treatment strategies including use of vaccines, drug delivery systems, and bio-
therapeutics approaches.  
A vaccination strategy is being implemented to trigger direct clearance of the causative 
parasites from the human host. However, the complex life-cycle of Plasmodium parasites with 
continuous antigenic mutations has partly hindered this approach so far.  The application of 
different types of drug delivery systems for the delivery of anti-malarial drugs is also being 
considered in order to improve the efficacy, pharmacokinetics, tolerability, and reduce toxicity 
of existing anti-malarial drugs. A third approach has emerged from the high success of 
antibodies to treat complex diseases like cancer and autoimmune diseases. Various antibody 
engineering methods and formats have been proposed to tackle the notable sophisticated life-
cycle of malaria.  
Within the malaria research field, the characteristics of these diverse treatment strategies, 
individually, are broadly acknowledged. This review article considers the current status of 
these approaches and the future outlook.  
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Introduction 
Malaria is an infectious disease that is caused by the parasite Plasmodium. This transmittable 
disease affects around 200 million annually, killing about 650,000 people per year, especially 
children less than 5 years old living in sub-Saharan Africa [1]. The WHO 2015 Fact Sheet 
reported that over 15 years (2000-2015), there was a global reduction in malaria incidence rates 
and mortality by 37% and 60%, respectively. However, the subsequent Fact Sheet in 2016 
confirmed the emergence of parasite resistance to antimalarial medicines and mosquito 
resistance to insecticides, which could trigger a rise in global malaria mortality if ignored. 
 
The five main parasite species in this respect are P. vivax,!P.knowlesi, P. ovale, P. malariae, 
and P. falciparum; the latter represents the most lethal [2]. The parasite life cycle in humans 
typically begins by injection of sporozoites via the skin, which can then migrate to hepatocytes 
in less than one hour [3], where they replicate and generate merozoites. These merozoites 
complete the journey to erythrocyts of the patient (clinical stage), and then differentiate into 
gametocytes that eventually reach the parasite holder (the mosquito) through infected human 
blood [4]. 
Various reports have indicated the growth in malaria mortality rate, due to emergence and 
spread of multidrug-resistant P. falciparum against established antimalarial compounds [5,6]. 
Moreover, therapeutic failure of some anti-malarial medications has been attributed to their 
toxic side effects as well as their inconvenient dosing schedules. Therefore, there is an urgent 
requirement to identify new treatment strategies against malaria [7]. These approaches have 
been directed towards enhancing the characterisation of natural products, adaptation of 
effective vaccine and drug delivery strategies, and the development of specific bio-therapeutic 
agents [8Ð13]. The main objective of this article is to review the anti-malarial role of bio-
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therapeutic formulations, and to evaluate their potential as effective treatments to malaria in 
the future.  
Vaccines and immune-conjugates 
Significant efforts have been dedicated over the past decades to develop vaccines that can 
protect humans against malaria parasites. Vaccine development has been directed to different 
infection stages including transmission blocking vaccines, pre-erythrocytic vaccines, and 
blood-stage vaccines; these have been reviewed comprehensively for both P. falciparum and 
P. Vivax [14Ð16]. Generally, vaccines have either been subunits of well-defined and conserved 
parasite antigens, or whole attenuated sporozoites. The most advanced malaria vaccine (RTS,S: 
MosquitixTM) is currently in Phase III clinical trial, and contains the conserved central repeat 
and C-terminal regions of the P. falciparum circumsporozoite protein (CSP) that is expressed 
on sporozoites in early liver stages [17,18]. Despite this advancement, vaccine development 
against malaria has been dishearteningly hindered by the complex life cycle of the parasites, 
which results in several morphological changes and displays antigenic variations.  
Immuno-conjugation refers to the use of a delivery system to deliver a conjugated drug to 
facilitate its delivery into a target tissue. An example of this strategy is the delivery of 
Angiopep-2 conjugated paclitaxel through the use of the low-density lipoprotein receptor-
related protein (LRP) as a carrier. This contrasts with the concept of drug delivery systems that 
can be used with either conjugated or unconjugated drugs [19].  Immuno-conjugation strategies 
can be used as "Trojan-horses" for specific delivery of antimalarial drugs, to reduce the 
emergence of resistant strains, and curtail the adverse drug reactions and toxicity of these 
medicines. This approach is broadly implemented in various medical applications, especially 
to target cancer cells [19Ð22]. Generally, anti-malarial conjugates can be ferried to the infected 
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host cells by parenteral routes through either passive or active targeting [23]. Passive targeting 
has been accomplished by conventional nano-carriers such as micelles, liposomes and 
polymerosomes [24Ð27]. Whilst, active targeting can be achieved by functionalisation of the 
nano-carriers with specific biomolecules such as antibodies, proteins, or peptides [23]. 
Considering the peculiarities of erythrocytes, liposomal nanocarriers are premeditated as a 
promising approach for the targeted delivery of antimalarial drugs [28]. For instance, 
artemether and lumefantrine were co-loaded into nanostructured lipid carriers, and their 
antiplasmodial effect was evaluated [29]. Similarly, curcuminoid-loaded liposomes in 
combination with arteether has prevented the recrudescence of malaria in mice [30]. An 
advancement to liposomal research was actualised through the introduction of nanomimics 
based on polymersomes for blocking invasion, and causing augmented exposure of the 
infective form of P. falciparum to the immune system [31]. Moreover, advanced drug delivery 
systems based on conjugation of, for example, artesunate to nanoerythrosomes have shown 
controlled delivery to evade drug leakage, improve stability, and reduce cost and toxicity [32]. 
Passive targeting could also be achieved by surface modification of the nano-carrier with 
poly(ethyleneglycol) (PEG) to delay phagocytosis, thus prolonging the plasma half-life of the 
drug, resulting in alteration in the pharmacokinetic profile of the drug [33]. Another 
conceptualisation has involved the iron uptake systems of microorganisms to deliver 
siderophoreÐdrug complexes, which are recognised by specific siderophore receptors, and is 
thereupon actively transported across the outer bacterial membrane [34], and could be useful 
against malaria [35]. Conjugation of desferrioxamine B to methyl anthranilic acid or nalidixic 
acid have, for instance, evinced significant effects against multidrug resistant P. falciparum 
[36].   
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The essential role of cysteine proteases in the malaria parasite is widely appreciated, and both 
small  inhibitors, like leupeptin and vinyl sulphones, and macromolecular inhibitors, such as 
falstatin expressed in P. falciparum, were analysed [37,38]. These promising macromolecule 
inhibitors are mostly competitive, and utilise loop-like structures to interact with malarial 
cysteine proteases [39]. A recent example has implemented computational approaches to better 
understand falcipains structure and ligand binding [40]. It is also essential when new drugs are 
established to concurrently study resistance processes in order to avoid a seemingly inevitable 
outcome [41]. The new approach of targeting "hot-spot" protein-protein interactions of 
macromolecular inhibitor-enzyme complexes is less liable to drug resistance point mutation, 
and represents a promising field in drug development. These hot spots can also include 
potential targetable steps in the protein export pathway that are essential for parasite survival 
[42]. Drug repurposing is another possibility to find approved drugs that could have efficacy 
against malaria parasites.  A recent example is illustrated by the development of the protein 
farnesyltransferase inhibitors (PFTIs), that block the transfer of a farnesyl group as a post-
translational modification onto specific proteins [43]. A panel of PFTIs was tested to inhibit in 
vitro growth of P. falciparum parasites, and a series of tetrahydroquinoline (THQ) PFTIs was 
identified with excellent potency [44].  
Delivery systems for anti-malarial drugs 
Since the initial conceptualisation of the "magic bullet" principle by Paul Ehrlich, which was 
based on specifically destroying foreign microbes without harming the human body itself, the 
drug delivery field has evolved noticeably. Drug delivery is based on using a delivery carrier 
to carry and release a therapeutic agent to a particular site in the body at a specific rate [45]. 
Different types of drug delivery systems can be used for this purpose including liposomes, 
niosomes, lipid nano-emulsions, poly(lactideco-glycolide) (PLGA), and natural polymers such 
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as collagen and chitosan [46Ð48]. The most commonly used delivery systems for the delivery 
of anti-malarial agents are summarised in Table 1. 
Liposomes are the most extensively studied system for the delivery of different therapeutic 
agents. As lipid based nanoparticles, they are formed by the self-assembly of their lipid 
components into bilayer structures encapsulating an aqueous moiety. This results in a versatile 
structure in which hydrophilic drugs can be encapsulated in the inner aqueous core while 
hydrophobic agents will be embedded in the lipid bilayer structure [49]. Several research 
groups have investigated the use of liposomal formulations for the delivery of different anti-
malarial agents in order to improve their pharmacokinetics or therapeutic index. Gabriels et al. 
(2003) developed a formulation that can improve patient compliance towards artesunate, which 
is an anti-malarial agents that requires frequent administration due to its rapid elimination, 
through the use of liposomes [50]. They developed a slow release preparation by encapsulating 
artesunate into liposomes containing egg-phosphatidylcholine/cholesterol in a molar ratio of 
4:3 [50]. 
Chloroquine (CQ) is an effective anti-malarial drug against all five species of parasites. The 
activity of CQ is thought to take place in the parasite's acidic digestive vacuole (DV) against 
the intraerythrocytic stage of the human malaria parasite [51]. However, inside the acidic DV, 
CQ becomes protonated and less membrane-permeable leading to its accumulation in the DV 
with subsequent efflux out of the DV, away from its primary site of accumulation and action, 
and reduction in the anti-malarial activity of CQ [52]. In order to reduce the efflux of CQ from 
DV, chitosanÐtripolyphosphate (CSÐTPP) nanoparticles (NPs) were conjugated to CQ and 
examined in Swiss mice infected with attenuated of P. berghei [11]. These NPs were 
demonstrated to act as an effective formulation, eliminating parasites, while protecting 
lymphocytes, serum and red blood cells against P. berghei infection at a dose of 250 mg/kg 
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body weight for 15 days treatment. Another approach was adopted using galactose coated poly-
l-lysine dendrimers loaded with CQ, and haemolytic toxicity was drastically reduced by at least 
50% through a sustained drug release behaviour compared to free CQ both in vitro and in vivo 
[53]. 
Primaquine (PQ) is another anti-malarial drug which exerts a broad spectrum activity against 
various stages of parasitic malaria. PQ targets latent liver stage of malaria infection caused by 
different plasmodia such as P. vivax and P. ovale [54]. Moreover, PQ is also prescribed for 
terminal prophylaxis to prevent infection by P. falciparum and P. vivax. However, PQ can 
cause severe tissue toxicity including haematological and gastrointestinal related side effects  
[55]. PQ targeting of the liver, would possibly help to reduce therapeutic dose and subsequently 
its dose related toxic effects. Encapsulation of PQ in different delivery systems such as 
liposomes was initially designed, and shown to significantly increase the LD50 and LD90 in 
mice, as a result of changing the distribution pattern of PQ after encapsulation [56]. In an 
attempt to target PQ to hepatocytes, Dierling et al. (2005) encapsulated PQ into chylomicron 
emulsion, with an average particle size of 180 nm, which led to significantly enhanced 
accumulation of PQ in the liver compared to free PQ [10]. Whilst the in vitro anti-leishmanial 
activity of PQ-loaded polyisohexylcyanoacrylate (PIHCA) NPs showed a 21-fold increase in 
ED50 compared with free PQ [57]. Moreover, when PQ was incorporated into an oral lipid 
nanoemulsion, PQ exhibited improved oral bioavailability, and was taken up preferentially by 
the liver with a drug concentration 45% higher than the free PQ. This resulted in a 25% lower 
dose required to achieve effective antimalarial activity against a P. bergheii infection in Swiss 
albino mice compared to free oral doses of PQ [58]. Other systems investigated for PQ delivery 
include dendrimeric NPs [59], poly(lactide) NPs [60], and the use of gum arabic microspheres 
[61]. 
9 
 
Anti-malarial antibodies 
Alternatively, the active targeting of malaria parasites can be achieved using antibodies, which 
has high proven efficacy against cancer and several other autoimmune diseases [62Ð65]. The 
antimalarial drug CQ showed improved efficacy when delivered inside immunoliposomes 
targeted with the pRBC-specific monoclonal antibody BM1234 [28]. Likewise, CQ-loaded 
MAb F10-liposomes were able to clear not only CQ-susceptible, but also CQ-resistant parasites 
in mice [66].!Antibodies are glycoproteins belonging to the immunoglobulin (Ig) superfamily, 
and have been widely used in different biomedical applications. The antibody molecule is 
structurally composed of two heavy and two light polypeptide chains, linked together by 
disulphide bonds [67]. One light chain type (λ or κ) can be linked to one heavy chain (µ, δ, γ1-
4, α1-2, or ε) to create any of the nine antibody subclasses in humans (IgM, IgD, IgG1-4, IgA1-2, 
or IgE) [68Ð72]. Functionally, an antibody consists of three fragments: a fragment crystallisable 
region (Fc) that represents the stem of the "Y" shaped molecule, and two fragment antigen-
binding (Fab) regions (Figure 1A). While the Fab fragments are responsible for antigen 
binding, the Fc fragment interacts with other elements of the immune system including Fc-
receptors (FcRs), pattern recognition receptors (PRR), and components of the complement 
cascade, to promote removal of the antigen [73,74]. Within the Fab region, each of the variable 
heavy (VH) or light (VL) chains consist of three complementarity determining regions (CDRs), 
which are accountable for antigen recognition [75]. 
Antibodies are prominent immune modulators that bridge innate and acquired immunity, and 
therefore, can be effective against micro-organisms, if they do not mediate a direct biological 
effect within the infection process [76]. This perception has sustained their candidacy to 
combat malaria by, for instance, curtailing the damage associated with any inappropriate host 
inflammatory responses [77]. The role of antibodies in malaria protection can also be attributed 
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to inhibition of merozoite invasion of erythrocytes [78], antibody-mediated phagocytosis 
through FcR and complement pathways [79], and antibody-dependent cellular inhibition 
[80,81]. Both autoantibodies and antibody immune complexes can drive B-cell responses, 
through the PRR toll-like receptor-9, and support their potential in malaria [82]. Several years 
of repeated infections are, however, required to develop protective responses to malaria [83], 
in defiance of the critical importance of humoral immunity in the development of acquired 
immunity to malaria [84,85].Variation of surface antigens and antigenic diversity facilitates the 
development of recurrent infections over the years, as new infections seem to exploit gaps in 
the repertoire of variant-specific antibodies [84,86]. P. falciparum expressed antigens on 
erythrocyte surfaces, for instance, appear to be highly polymorphic and undergo clonal 
antigenic diversity, and antibodies against these antigens typically inaugurate a high degree of 
strain specificity [87,88]. 
Previous studies have acknowledged the fact that upon exposure to a new malaria infection, 
parasite-specific antibody levels rise noticeably within 1-2 weeks [89,90]. The boosted 
antibodies then reduce quickly after the infection is controlled, and accordingly signify that 
protective memory for a specific antibody response is either not provoked or is being 
debilitated [91].  Passive transfer of IgG from immune African adults to African children was 
observed to be highly effective against malaria parasites [80,92]. Furthermore, transfer of 
serum from partially immune individuals to non-immune persons induces significant anti-
malarial activity [92,93]. This anti-malarial response was verified to be associated with malaria 
specific antibodies [94,95]. Nevertheless, serum therapy is notoriously correlated with high 
difficulty of finding a sufficient number of donors, possibility of transferring other infectious 
diseases, and the impracticality of dealing with human blood products. In addition, sera 
normally consists of polyclonal antibodies, which might contain numerous nonspecific 
antibodies [96,97]. Consequently, serum treatment is associated with several limitations, and 
11 
 
adoption of a bespoke antibody engineering approach is essential to match the sophisticated 
life cycle of this parasite and the scale of this ubiquitous disease.  
Amongst the four IgG subclasses, anti-malarial protective antibodies are restricted to a panel 
of IgG1 and IgG3 subclasses [81]. The IgG2 subclass can compete with IgG1 and IgG3, and 
interfere with their protection effectiveness [98], although others have suggested IgG2 
antibodies participate in protection if individuals possess a rare mutated allele encoding an Fc 
gamma receptor-type IIA (FcγRIIA) that can bind IgG2, IgG3, and IgG1 subclasses [99]. On 
the other hand, IgG4 antibodies are considered as completely non-protective [98,100Ð102]. 
Subsequently, the IgG3 subclass is epitomised as the prevailing isotype of antibody responses 
incarnated with protection against malaria [101Ð103]. The propagated antibodies were 
primarily of the IgG2a and IgG3 subclasses [104,105]. In addition, immunisation with an 
antigen preparation derived from P. falciparum merozoite surface protein (MSP)-1 has induced 
a shift to IgG2b [106], even though most protein antigens in a murine model are expected to 
induce IgG1 antibodies. Interestingly, mouse IgG2b is to a certain degree the equivalent of 
human IgG3 [107], and has a shorter half-life than other mouse IgG subclasses [108]. 
Consequently, a human vaccine aimed at eliciting antibody protection against blood-stage P. 
falciparum would preferentially generate IgG1 and/or IgG3 antibody responses against the 
selected candidate antigens, and downregulate a concomitant IgG4 and IgG2 antibody 
response. Therefore, an anti-malarial vaccine should ideally be administered in combination 
with an adjuvant that stimulates the production of cytokines, such as interleukin (IL)-10 and/or 
transforming growth factor (TGF)-β [109,110], in target cells to switch Ig responses to IgG1 
and IgG3.  
Along with IgG class, other Ig classes were explored to envisage whether infection with 
Plasmodium parasites can be preferentially inhibited. The therapeutic inappropriateness of IgE 
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antibodies to treat malaria was commonly suggested, due to their observed role in malaria 
pathogenesis [111,112]. Nevertheless, a reduced risk of subsequent malaria infection was also 
linked to the existence of high levels of parasite-specific IgE antibodies [113]. Pentameric IgM 
antibodies were additionally implemented as an adjuvant for malaria vaccine development, 
through their ability to stimulate the development of acquired T-cell immunity [114]. Whilst 
the ability to steer IgA antibodies to target FcαR have shown remarkable potential in 
eliminating serum pathogens [115]. Re-appraisal of the role of IgA in malarial infections is 
necessary, since Plasmodium-specific IgA antibodies were detected at high levels in humans 
breast milk [116,117] and serum [118].  
Different antibody formats can be accoutred to neutralise Plasmodium parasites, ranging from 
a full monoclonal antibody (mAb) to smaller fragments including Fab, a single chain antibody 
(scFv), or even a single domain antibody (sdAb) (Figures 1 and 2). Whole mAbs are time-
honoured bio-therapeutic molecules, through their ability to maximise the benefits of activating 
the cellular response by Fc regions [119]. In the murine malaria model, the recruitment of 
effector cells by Fc is vital, as the passive transfer of specific antibodies to malarial MSP1 
could not impede death in FcR-deficient and immunodeficient models [81,120]. However, the 
utilisation of mAbs in malaria might be inappropriate per se, especially if these antibodies 
interact with the incongruously inhibitory FcRs [115]. Moreover, high concentrations of anti-
malarial mAbs are requisite to compete for FcRs binding with infection induced low-affinity 
polyclonal antibodies [121]. These low-affinity antibodies were developed against short highly 
repetitive amino acid sequences, cross-reactive with several malarial antigens, and might be 
generated from a process of immune evasion [122].  
In order to develop a Òmagic bulletÓ that would specifically neutralise and eradicate invading 
microbes, like malaria parasites, various antibody engineering approaches and formats have 
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been investigated. This includes bispecific antibodies (BsAbs) that were developed to 
recognise both P. yoelii MSP1 and human FcγR1 [9]. Another bispecific scFv combination, 
linked by a flexible peptide linker (Gly4-Ser)3, has been developed to target P. falciparum 
blood-stage malaria parasites, by linking CD3 antigen of human T-cells and MSP1[123]. Even 
a trispecific antibody has been developed in the malaria field, as previously involved in cancer 
treatment development, to link two potential targets of malaria [merozoite surface protein 1 
(MSP1) and malarial Apical Membrane Antigen-1 (AMA1)] with FCR [9,124]. An alternative 
antibody format, which has been extensively used in malarial research, is the binding ÒarmÓ 
Fab fragment. The comprehensive search for anti-malarial antibodies in the Protein Data Bank 
(PDB) has retrieved eleven mouse Fabs that were developed against different malaria targets 
(Table 2). The smallest binding domains, camelids (VHH) and shark (VNAR) sdAbs (Figure 
1 C and D), can also be used to neutralise malaria parasites since they are highly acclaimed to 
bind cryptic epitopes [125Ð127]. These cryptic cavities and clefts are secluded to full mAbs 
due to steric hindrance, and therefore, can be conveniently accessed by smaller sdAbs (Figure 
2). The selection and affinity maturation of two shark VNARs (PDB ID: 1VES and 1VER) 
targeting P. falciparum AMA1 were developed for diagnostic applications [128], as 
summarised in Table 2. Unusually, CDR3 of the 1VES sdAb has displayed an extended-hairpin 
structure (Figure 2), which has indulged this sdAb with a distinct selective advantage in 
accessing cryptic epitopes [129]. To achieve a comparable objective, camel VHH sdAb (PDB 
ID: 4GFT) was generated to target MyoA-binding domain (D3) of P. falciparum myosin tail 
interaction protein (MTIP) [130]. This sdAb binds favourably to an area that is slightly 
overlapping with the MyoA binding groove, and impedes MyoA binding by MTIP. Antibodies 
have been thoroughly investigated in targeting specific malarial antigens and antimalarial drugs 
for both therapeutic [131Ð137] and diagnostic [138Ð141] purposes. Moreover, antibodies 
possess high potential to deliver anti-malarial drugs directly to parasites, thus reducing the risk 
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of adverse drug reactions.  However, the exploitation of antibodies with respect to this concept 
remains not fully explored, and requires further pursuance in the future. 
Future perspectives 
Malaria is a highly infectious disease that has diminished the lives of millions around the globe. 
Treatment strategies to date are based on either natural/synthetic small molecules, or 
macromolecules such as vaccines and antibodies. Most treatment approaches have been 
hindered by the complex life-cycle of the parasite that has continuously caused the emergence 
of drug-resistant species. Despite this unprecedented difficulty, several promising drug 
delivery approaches, vaccines, and antibody formats have been developed to tackle this fatal 
disease. Future research should be directed to find new antimalarial candidates with either new 
mechanisms of action, resistance modifying actions or target novel metabolic pathways that 
are essential for parasite survival and applying new tools for designing these drugs. In addition, 
more novel combinations of small molecules or micro-macro complexes should be 
implemented as combination strategies or antibody-small molecule drug conjugates to 
synergise the treatment effect. In order to achieve this objective, additional funding is required 
to support the drug discovery process academically, and to attract pharmaceutical companies 
to invest within this highly pandemic, but not very commercially-attractive field.  
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Figure legends 1 
Figure 1: Antibody structure and alternative formats 2 
The refined structures of A) IgG2a mAb (PDB ID: 1IGT), and B) scFv formats of the same 3 
antibody for illustration. The antibody domains were colour coded as follow; VL: red, VH: 4 
blue, CL: green, CH1: yellow, CH2:  magentas/orange, CH3: cyan/grey and, and Linker: light 5 
grey. The IgG mAb is composed of two Fab and one FC regions. C) VNAR sdAb (PDB ID: 6 
1VES), and D) VHH sdAb (PDB ID: 4GFT). The atoms of C) and D) were coloured as carbon: 7 
green; Oxygen: red; nitrogen: blue. Structures were viewed and coloured by PyMOL 1.3 8 
(academic version). 9 
Figure 2: Binding site topography and CDRs orientation 10 
CDRs orientation of Fab (PDB ID: 2J5L), VHH (PDB ID: 4GFT), and VNAR (PDB ID: 1VES) 11 
domains were examined as top (T) and side (S) views. The CDR regions were colour coded for 12 
CDR1: red, CDR2: green, CDR3: blue, HV2 (1VES VNAR): yellow, and HV4 (1VES VNAR): 13 
magenta, CDRL1 (2J5L): cyan, CDRL2 (2J5L): orange, CDRL3 (2J5L): violet. The PDB 14 
entries of these crystal structures are depicted at the lower corner of each picture. Structures 15 
were viewed by PyMOL 1.3 (academic version). 16 
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Table 1: Outline of the anti-malarial drug delivery systems  
 
Anti-malarial 
drugs 
Delivery system used Purpose Reference 
artesunate liposomes 
Improve patient compliance for 
multiple administations 
[50] 
chloroquine 
chitosanÐtripolyphosphate 
nanoparticles 
Treatment of chloroquine resistant 
malaria parasites 
 
[11] 
chloroquine dendrimers Reduce chloroquine toxicity [53] 
primaquine liposomes Reduce  primaquine toxicity [56] 
primaquine chylomicron emulsion Target primaquine to hepatocytes [10] 
primaquine 
polyisohexylcyanoacrylate 
(PIHCA) nanoparticles 
Reduce  primaquine toxicity [57] 
primaquine oral lipid nanoemulsion 
Improved primaquine oral 
bioavailability and liver targeting 
[58] 
chloroquine 
PEGylated poly- 
L 
-lysine-based dendrimers 
 
To induce controlled and sustained 
delivery 
[142] 
chloroquine 
PEGylated Neutral and 
Cationic Liposomes 
 
Treatment of chloroquine resistant 
malaria parasites 
 
[143] 
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chloroquine 
amidated pectin hydrogel 
beads 
 
Delay the release of oral 
chloroquine to distal parts of the 
gastrointestinal tract 
[144] 
chloroquine 
and 
primaquine 
dendritic derivatives 
 
Reduce the toxicity of the used 
anti-malarial drugs 
[145] 
chloroquine poly(amidoamines) drug 
conjugates 
Selectively deliver chloroquine to 
Plasmodium-infected red blood 
cells 
[146] 
monensin 
 
Liposomes 
Improving the anti-malarial 
activity of monensin 
 
[147] 
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Table 2: Summary of the crystal structures retrieved from the PDB 
PfRH5: P. falciparum reticulocyte-binding protein homologue 5; Pvs25: P. vivax P25 protein; 
AMA-1: Malarial Apical Membrane Antigen-1; PfEBA-175: P. falciparum EBA-175; MSP1: 
Merozoite surface protein 1; MyoA- MTIP: myosin A- myosin tail interaction protein; Fab: 
fragment antigen-binding; VNAR: single variable new antigen receptor domain antibody 
fragments; VHH: variable domain of heavy chain antibodies. 
 
 
PDB 
entry 
Resolution 
() 
Species Format Target Reference 
 
1 4U1G 3.1 Mus musculus  Fab PfRH5 [131]  
2 4U0R 2.3 Mus musculus  Fab PfRH5 [131]  
3 1Z3G 3.3 Mus musculus  Fab  Pvs25 [148]  
4 2Q8B 2.3 Mus musculus   Fab AMA1 [132]  
5 2Q8A 2.4 Mus musculus  Fab AMA1 [132]  
6 3S62 4.01 Mus musculus  Fab Pvs25 [133]  
7 4QEX 4.5 Mus musculus  Fab PfEBA-175 RII [134]  
8 4K2U 2.45 Mus musculus  Fab PfEBA-175 F1 [134]  
9 2J5L 2.9 Mus musculus  Fab AMA1 [135]  
10 2J4W 2.5 Mus musculus  Fab AMA1 [135]  
11 1OB1 2.9 Mus musculus  Fab MSP1-19 [136]  
12 
1VER 
2.82 
Orectolobus 
maculatus  VNAR AMA1 
[129] 
 
13 
1VES 
2.18 
Orectolobus 
maculatus  VNAR AMA1 
[129] 
 
14 4GFT 1.6 Lama glama  VHH MyoA-MTIP [130]  
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